Nuformix plc (LON:NFX – Get Free Report)’s share price dropped 12.8% on Tuesday . The stock traded as low as GBX 0.20 and last traded at GBX 0.24. Approximately 52,902,176 shares were traded during mid-day trading, an increase of 115% from the average daily volume of 24,560,514 shares. The stock had previously closed at GBX 0.27.
Nuformix Stock Down 9.8%
The business has a fifty day moving average price of GBX 0.27 and a 200-day moving average price of GBX 0.21. The company has a market cap of £4.28 million, a P/E ratio of -0.52 and a beta of 1.22.
Nuformix (LON:NFX – Get Free Report) last announced its earnings results on Tuesday, January 27th. The company reported GBX (0.04) earnings per share for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Stories
- Five stocks we like better than Nuformix
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- Refund From 1933: Trump’s Reset May Create Instant Wealth
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
